Urgo Medical is all about being right at the heart of the action
9 subsidiaries in our main markets
Rua Jaguarão, 95
Chácaras Reunidas.
São José dos Campos
Tel. 55.12.3202.1306
Fax. 55.12.3202.1302
www.curatec.com.br
E2, Floor 26, Junyao International Plaza,
No.789 Zhaojiabang Road
Shanghai 200032, China
Tel. 86.10.643.792.82
Fax. 86.10.643.579.27
www.urgo.cn
42, rue de Longvic
BP 157
21304 Chenôve CEDEX
Tel. +33.380.54.50.00
Fax. +33.380.44.74.52
www.urgomedical.fr
Justus Von Liebig
Strasse 16
66280 Sulzbach
Tel. 49.68.97.57.90
Fax. 49.68.97.57.92.12
www.urgo.de
Trakt Lubelski 135
04-790 Warszawa
Tel. 022.616.33.48
Fax. 022.617.69.21
www.bioprofil.pl
Edificio L’Illa Diagonal
Diagonal, 569, 2ª planta
08029 Barcelona
Tel. +34.93.494.14.95
Fax. +34.93.419.25.92
www.urgomedical.es
PRODUCT CO LTD
10th FI., Dr Gerhard Link Bldg.
88 Krungthepkreetha Rd.
Huamark, Bangkapi,
Bangkok 10240, Thailand
Tel. 662.379.42.634
Fax. 662.379.42.65
Sullington Road
Shepshed - Loughborough
Leicestershire
Tel. 44.1509.50.20.51
Fax. 44.1509.65.08.98
www.urgo.co.uk
PRODUCTS CO.
Nam A Tower Fl. 10
201-203 Cach Mang Thang Tam, District 3
Ho Chi Minh City, Vietnam
Tel. 84.8.3827.3720
Fax. 84.8.6290.5899
www.urgo.vn
Historically a European player, with subsidiaries in all principal markets, Urgo Medical is now also established firmly in Asia, supported by its subsidiaries in China and Thaïland and its sales offices in Vietnam.
An extensive network of importers and distributors complete its coverage in mature markets, where Urgo Medical is constantly consolidating its position.
Products for an international market
Our products are developed within a global context, by multicultural teams supported by regulatory experts with in-depth knowledge of the world’s different health systems.
Constructive and demanding dialogue with the authorities governing the different markets and a relationship of proximity with health professionals guarantees that all our solutions are appropriate to specific local circumstances.
Global ambitions
Emerging markets account for 11 % of the global health market and 50 % of our growth. We are considering major investment in Asia (China and Korea), Central Europe (Poland and Russia) and Latin America. We now have the resources needed to develop in this latter region, having taken over a leading company in Brazil at the end of 2011.
To consolidate our leading position in Europe, we plan to create a more extensive network in Western Europe e.g. the recent creation of a Dutch subsidiary.